Bentley’s BeGraft Plus for BEVAR Receives CE Mark Approval

November 19, 2025—Bentley InnoMed GmbH announced CE Mark approval for the company’s BeGraft Plus for use as a bridging stent graft in branched endovascular aneurysm repair (BEVAR), expanding Bentley’s portfolio for complex aortic interventions. According to the company, the extended length range of up to 78 mm provides physicians with an on-label solution for the BeGraft Plus that allows bridging longer distances in challenging anatomies.

The BeGraft Plus with the BEVAR indication is now available in markets where local regulatory clearance has been granted. The first clinical cases under the new indication are expected in the coming weeks, stated the company.

Bentley advised that the BeGraft Plus stent graft system is indicated for permanent intraluminal placement in the iliac and renal arteries to restore or improve vessel patency, and to seal aneurysms, acute perforations, ruptures, and fistulas. Additionally, the BeGraft Plus is indicated for use as a bridging stent graft in patients requiring endovascular abdominal aortic aneurysm repair with a branched aortic endovascular graft to keep the visceral arteries perfused, noted the company.

Martin Austermann, MD, a vascular surgeon at St. Franziskus Hospital and Assistant Professor of Vascular Surgery at the University of Münster in Münster, Germany, serves as a coordinating investigator of the clinical BEVAR study.

“In branched aortic repair, how a device behaves in real anatomy is critical,” commented Dr. Austermann in Bentley’s press release. “BeGraft Plus provides the radial support needed for stable apposition, along with the flexibility to accommodate patient-specific anatomy. The initial clinical experience is encouraging, and having an on-label option for use as a bridging stent in BEVAR procedures offers physicians an important additional choice in complex aortic repair.”